Not So NICE: How Market Access Schemes Impact the CMO Sector
List Price: US $997
Delivery format: Electronic PDF delivery within one business day upon payment.
*This report is included at no extra cost for STRATEGIC ADVANTAGE clients, and is accessible in the Trend Reports section here. Learn more about PharmSource STRATEGIC ADVANTAGE outsourcing intelligence portal.
This 15-page expert analysis explains why economic austerity forces Europe’s state-funded health-care systems to limit patient access to just those pharmaceuticals with clearly proven health and cost benefits. Contract manufacturing organizations (CMOs) should prepare themselves for similar de-facto drug rationing in the United States and elsewhere.
This Trend Report presents detailed research and analysis of how European drug-rationing policies could affect pharmaceutical manufacturing profitability – and future operations – in the EU, US and elsewhere.
PharmSource’s expert researchers examine in-depth how European health systems in the United Kingdom and Germany have impacted drug approvals in the past several years – and the consequences of those drug-approval regimens and pricing policy decisions for CMOs.
Who should buy this report?
This 15-page report provides information that you won’t find in any other source. This report is required reading for:
• CMO executives
• Bio/pharmaceutical sourcing and procurement executives
• Private equity investors
Published June 2014